pre-IPO PHARMA

COMPANY OVERVIEW

Longevity Biotech is a preclinical research and development company. Our efforts are centered on the development of novel therapeutics that will have direct clinical impacts on patients lives. All of our programs are based on our proprietary Hybridtide peptide scaffold technology.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Metabolic Disorders
  • Neurological Disorders

  • WEBSITE

    http://longevitybiotech.com/


    CAREER WEBSITE

    http://longevitybiotech.com/careers-2/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jul 16, 2018

    Longevity Biotech Initiates Clinical Neuroinflammation Biomarker Study at the Department of Veterans Affairs to Investigate Immune Related Aspects of Parkinson's Disease With Continued Support From the Michael J. Fox Foundation


    Jan 2, 2018

    Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma


    Oct 27, 2017

    Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis


    Oct 11, 2017

    Longevity Biotech Granted US Patent Covering Hybridtide Platform Technology for Stabilized Peptide Therapeutics


    Feb 7, 2017

    Longevity Biotech and University of Nebraska Medical Center Awarded Continuing Grant from the Michael J. Fox Foundation for Parkinson's Research


    For More Press Releases


    Google Analytics Alternative